CN112439132B - Device for improving arthritis using ceramic composition and low intensity ultrasonic wave - Google Patents
Device for improving arthritis using ceramic composition and low intensity ultrasonic wave Download PDFInfo
- Publication number
- CN112439132B CN112439132B CN201911228027.5A CN201911228027A CN112439132B CN 112439132 B CN112439132 B CN 112439132B CN 201911228027 A CN201911228027 A CN 201911228027A CN 112439132 B CN112439132 B CN 112439132B
- Authority
- CN
- China
- Prior art keywords
- ceramic composition
- inflammation
- far infrared
- intensity ultrasonic
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 239000000919 ceramic Substances 0.000 title claims abstract description 72
- 206010003246 arthritis Diseases 0.000 title claims abstract description 62
- 206010061218 Inflammation Diseases 0.000 claims abstract description 66
- 230000004054 inflammatory process Effects 0.000 claims abstract description 66
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 39
- 230000000638 stimulation Effects 0.000 claims abstract description 28
- 238000010438 heat treatment Methods 0.000 claims abstract description 13
- 238000010298 pulverizing process Methods 0.000 claims description 34
- 238000010304 firing Methods 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 21
- 238000000465 moulding Methods 0.000 claims description 19
- 238000005498 polishing Methods 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000004575 stone Substances 0.000 claims description 13
- 229910052626 biotite Inorganic materials 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 239000011435 rock Substances 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 19
- 230000001939 inductive effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 11
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 10
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 238000005520 cutting process Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000001678 irradiating effect Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 239000010946 fine silver Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229910020175 SiOH Inorganic materials 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229910052875 vesuvianite Inorganic materials 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
- C04B35/16—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay
- C04B35/18—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay rich in aluminium oxide
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/34—Non-metal oxides, non-metal mixed oxides, or salts thereof that form the non-metal oxides upon heating, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3427—Silicates other than clay, e.g. water glass
- C04B2235/3463—Alumino-silicates other than clay, e.g. mullite
- C04B2235/3472—Alkali metal alumino-silicates other than clay, e.g. spodumene, alkali feldspars such as albite or orthoclase, micas such as muscovite, zeolites such as natrolite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/34—Non-metal oxides, non-metal mixed oxides, or salts thereof that form the non-metal oxides upon heating, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3427—Silicates other than clay, e.g. water glass
- C04B2235/3463—Alumino-silicates other than clay, e.g. mullite
- C04B2235/3481—Alkaline earth metal alumino-silicates other than clay, e.g. cordierite, beryl, micas such as margarite, plagioclase feldspars such as anorthite, zeolites such as chabazite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/42—Non metallic elements added as constituents or additives, e.g. sulfur, phosphor, selenium or tellurium
- C04B2235/422—Carbon
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/65—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes
- C04B2235/656—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes characterised by specific heating conditions during heat treatment
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/65—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes
- C04B2235/656—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes characterised by specific heating conditions during heat treatment
- C04B2235/6567—Treatment time
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pathology (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
The present invention relates to a device for relieving and improving inflammation using a far infrared ray emitting ceramic composition and low intensity ultrasonic waves, and more particularly, to a device for relieving and improving inflammation, comprising: an ultrasonic irradiation unit that generates low-intensity ultrasonic waves to irradiate a site where inflammation occurs; a thermal stimulation unit for applying far infrared rays generated by heating the ceramic composition to an inflammation site; and a control unit for controlling at least one of a frequency band, intensity, and irradiation time of the low-intensity ultrasonic wave and the temperature of the thermal stimulation unit. The above-mentioned device for relieving and improving inflammation warmly stimulates the inflammation site with the ceramic composition radiating a large amount of far infrared rays, thereby fundamentally relieving and improving inflammation. And, the ceramic composition radiating a large amount of far infrared rays is used to warm-stimulate the bone tissue site damaged by arthritis, thereby improving and treating the bone tissue damaged by arthritis.
Description
Technical Field
The present invention relates to a device for relieving and ameliorating inflammation using a far infrared ray emitting ceramic composition and low intensity ultrasonic waves, which shows a substantial effect of relieving and ameliorating inflammation by stimulating a site of inflammation with heat using a ceramic composition emitting a large amount of far infrared rays, and irradiating low intensity ultrasonic waves which increase cell movement or growth factor synthesis and decrease expression of inducible nitric oxide synthase protein.
Further, the present invention relates to an apparatus for improving and treating bone tissue damaged by arthritis using a far infrared ray emitting ceramic composition and low intensity ultrasonic waves, and more particularly, to an apparatus for improving and treating bone tissue damaged by arthritis by increasing bone volume, increasing bone section thickness and reducing the number of average section fragments by thermally stimulating a bone tissue site damaged by arthritis with a ceramic composition emitting a large amount of far infrared rays, and irradiating low intensity ultrasonic waves.
Background
The immune response occurring in daily life is a physiological protective activity occurring inside the human body, and inflammation is one of the immune responses that can be confirmed by our naked eyes. Inflammation causes various visible physiological phenomena such as fever, vasodilation, and swelling, increases vasodilation and vascular permeability of blood vessels when inflammation is promoted by inflammatory reaction mediators, and collects and activates granulocytes, dendritic cells, B cells, and the like having phagocytosis. When an inflammatory response begins, cytokines (cytokines) are excessively secreted to cause diseases associated with inflammation, and Inducible Nitric Oxide Synthase (iNOS) expressed by inflammatory cytokines promotes the production of Nitric Oxide (NO).
Nitric oxide plays an important role in our body in cases where it kills bacteria to participate in the immune response, but it is known that excessive secretion of nitric oxide can lead to deeper inflammatory responses in the host, with negative consequences.
Inflammatory diseases are one of the leading causes of death worldwide. Inflammatory diseases affect various organs and tissues, for example, blood vessels, heart, brain, nerves, joints, skin, lungs, eyes, gastrointestinal tract, kidneys, thyroid, adrenal glands, pancreas, liver, and muscles. The treatment of inflammatory diseases is a subject of interest to pharmaceutical companies and researchers. Although many studies have been recently conducted in this field, and current therapies for inflammatory diseases include alleviation of symptoms with non-specific drugs as well as reduction of inflammation, delay of progression of diseases, etc., these therapies have serious problems of drug side effects, tolerance, etc.
Arthritis and other diseases of the musculoskeletal system are reported to be the most common cause of disability in adults. Arthritis is a refractory disease as follows: in the early stage, the deformation of the articular cartilage begins, but pain and stiffness due to destruction of the articular cartilage and subchondral bone gradually occur. As conventional arthritis treatment methods, there have been used drug therapy for reducing inflammation, micro-perforation as a surgical method for inducing cartilage regeneration, artificial joint replacement in which an artificial joint is substituted for a large damaged portion, and the like. They are mainly used as a treatment method for joints, and a treatment therapy for bone tissue damaged by arthritis is still insufficient.
The far infrared rays are not absorbed and reflected by the living body unlike visible or near infrared rays, but absorbed by the living body and permeated into the living body by means of permeability to generate self-heating, thereby not only bringing about a warming effect and a sweating effect, but also promoting metabolism, improving blood circulation, restoring enzyme production and activating aging cells, thereby promoting excretion of waste and unnecessary fat, inhibiting production of lactic acid, free fatty acids, fatty acid esters, cholesterol, excessive salts and uric acid, which cause fatigue or aging, and maintaining health and young.
When far infrared rays exhibiting the effects as described above are used in combination with thermotherapy, house-shaped or band-shaped products are disclosed as a solution for relieving muscle pain, arthritis, and pain caused thereby.
On the other hand, it is known that low-intensity ultrasound changes the cell membrane permeability of adjacent cells and converts Ca 2+ Ion induction into the cell, thereby increasing intracellular Ca 2+ Concentration, this intracellular change has a beneficial effect on wound healing by increasing cellular motility or growth factors. In addition, it has effects of inducing secondary physiological reactions, such as increasing blood flow, increasing metabolism, increasing collagen tissue elongation, increasing pain threshold, relieving muscle spasm, increasing enzyme activity, changing skeletal muscle contractility, etc. In recent years, it has been known that when ultrasound is applied to a joint region, ultrasonic vibration is transmitted to chondrocytes in cartilage tissue to directly affect the activation of the chondrocytes, and therefore, degenerative arthritis caused by the decrease in the activity of the chondrocytes can be treated.
Documents of the prior art
Patent literature
Korean patent publication: no. 10-2003-0079902 (2003.10.10)
Korean patent authorization: no. 10-0537343 (2005.12.12)
Disclosure of Invention
Technical problem
The present invention is directed to provide a device for thermally stimulating an inflammation site using a ceramic composition emitting a large amount of far infrared rays, and fundamentally relieving and improving inflammation by irradiating low-intensity ultrasonic waves, which increase cell movement and growth factor synthesis and reduce the expression of Inducible Nitric Oxide Synthase (iNOS) protein.
Also, the site of inflammation may be a site of bone tissue damaged by arthritis, thereby providing a means for improving and treating bone tissue damaged by arthritis.
Means for solving the problems
The object of the present invention is achieved by providing a composition comprising: an ultrasonic irradiation unit that generates low-intensity ultrasonic waves to irradiate a site where inflammation occurs; a thermal stimulation unit for applying far infrared rays generated by heating the ceramic composition to a site where inflammation occurs; and a control unit for controlling at least one of the frequency band, intensity and irradiation time of the low-intensity ultrasonic wave and the temperature of the thermal stimulation unit, and is realized by using a far infrared ray emitting ceramic composition and a device for relieving and improving inflammation using the low-intensity ultrasonic wave.
In one embodiment of the present invention, the inflammation site may be a bone tissue site damaged by arthritis, and thus the bone tissue site damaged by arthritis may be improved and treated.
According to a preferable feature of the present invention, the control unit controls the low-intensity ultrasonic waves to have a frequency band of 0.5MHz to 1.5MHz and a frequency of 100mW/cm 2 To 150mW/cm 2 The strength of (2).
According to a more preferable feature of the present invention, the control unit controls the low-intensity ultrasonic waves to have a frequency band of 1.1MHz and 120mW/cm 2 Strength of (1): 9 pulse duration, 50% duty cycle.
According to a further preferred feature of the present invention, the control unit controls the low-intensity ultrasonic waves to have an irradiation time of 15 to 25 minutes each time.
According to a still further preferred feature of the present invention, the control unit controls the low-intensity ultrasonic waves to have an irradiation time of 20 minutes each time.
According to a still further preferred feature of the invention, the control portion controls the thermal stimulation portion to be heated to a temperature of 35 ℃ to 40 ℃.
According to a further preferable feature of the present invention, the control unit controls the thermal stimulation unit to heat the thermal stimulation unit to a temperature of 38 ℃.
According to a still further preferred feature of the invention the ceramic composition comprises Maifanitum, volcanic rock, carbon, volcanic ash and biotite.
According to a still further preferred feature of the present invention, the above ceramic composition consists of 100 parts by weight of medical stone, 0.5 to 1.5 parts by weight of vesuvianite, 0.05 to 0.15 parts by weight of carbon, 1 to 3 parts by weight of volcanic ash, and 0.5 to 1.5 parts by weight of biotite.
According to a further preferred feature of the invention, the ceramic composition is prepared by the steps of: crushing the raw materials, namely respectively crushing medical stone, volcanic rock, carbon, volcanic ash and biotite; a micro-pulverization step of mixing pulverized materials respectively pulverized by the raw material pulverization step, adding water, and then performing micro-pulverization; an air injection step of injecting air so that the finely pulverized material obtained by the fine pulverization step has a particle shape; a molding step of putting the micro ground matter having the particle shape in the air injecting step into a mold and performing pressure molding; a firing step of firing the molded article molded in the molding step; and a polishing step of polishing the surface of the molded product fired in the firing step.
According to a further preferred feature of the present invention, a step of coating the pulverized material pulverized in the fine pulverization step with silver nanoparticles is further performed between the fine pulverization step and the air injection step.
According to a further preferable feature of the present invention, in the micro-pulverization step, pulverized materials respectively pulverized by the raw material pulverization step are mixed to prepare a mixture, and 60 to 80 parts by weight of water is added to 100 parts by weight of the mixture, and then pulverized into a size of 1000 to 3000 mesh.
According to a still further preferable feature of the present invention, in the above-mentioned firing step, the molded article molded by the above-mentioned molding step is fired at a temperature of 900 to 1200 ℃ for 10 to 24 hours.
Further, the object of the present invention can be achieved by providing a method for operating an apparatus for ameliorating and relieving an inflammation site, the method comprising: generating the low-intensity ultrasonic wave to irradiate an inflammation part; applying far infrared rays generated by heating the ceramic composition to an inflammation site; and controlling at least one of a frequency band, intensity, and irradiation time of the low-intensity ultrasonic wave to be irradiated, and a heating temperature of the ceramic composition.
In one embodiment of the present invention, the site of inflammation may be a bone tissue site damaged by arthritis.
According to a preferred feature of the invention the controlling step is carried out to control the low intensity ultrasound to be in a frequency band of 0.5MHz to 1.5MHz and at 100mW/cm 2 To 150mW/cm 2 Is irradiated with light of an intensity of (1).
According to a more preferred feature of the invention the controlling step is carried out to control the low intensity ultrasound to have a frequency band of 1.1MHz and 120mW/cm 2 Strength of (1): 9 pulse duration, 50% duty cycle.
According to a further preferred feature of the present invention, the ultrasonic wave controlled by the above-mentioned control step is irradiated at a frequency of 2 to 4 times per week for 3 to 5 weeks for 15 to 25 minutes each time.
According to a further preferred feature of the invention, the ultrasonic waves controlled by the above-mentioned control step are irradiated for 4 weeks at a frequency of 3 times per week for 20 minutes each.
According to a still further preferable feature of the present invention, in the controlling step, a heating temperature of the ceramic composition is controlled to 35 ℃ to 40 ℃.
According to a still further preferred feature of the present invention, in the controlling step, a heating temperature of the ceramic composition is controlled to 38 ℃.
According to a further preferred feature of the invention, the ceramic composition heated by the above-mentioned control step is applied to the site of inflammation at a frequency of from 4 to 6 times per week for from 3 to 5 weeks for from 40 to 80 minutes per time.
According to a further preferred feature of the invention, the ceramic composition heated by the above-mentioned control step is applied to the site of inflammation at a frequency of 5 times a week for 4 weeks at 60 minutes each time.
ADVANTAGEOUS EFFECTS OF INVENTION
The device for relieving and improving inflammation using far infrared ray radiating ceramic composition and low intensity ultrasonic wave according to the present invention shows excellent effects of fundamentally relieving and improving inflammation by warm-stimulating an inflammation site by the ceramic composition radiating a large amount of far infrared rays, increasing movement of cells or synthesis of growth factors and reducing expression of inducible nitric oxide synthase protein by irradiation of low intensity ultrasonic wave.
Also, the device for improving and treating bone tissue damaged by arthritis using the far infrared ray radiating ceramic composition and low intensity ultrasonic wave according to the present invention shows excellent effects of improving and treating bone tissue damaged by arthritis by radiating low intensity ultrasonic wave by increasing bone volume, increasing bone section thickness and reducing the number of average section fragments by stimulating the bone tissue site damaged by arthritis with ceramic hyperthermia radiating a large amount of far infrared ray.
Drawings
FIG. 1 is a graph showing analysis of inducible nitric oxide synthase protein of macrophages (Raw 264.7 cells) treated by Experimental example 1 of the present invention by Western blot (Western blot).
Fig. 2 is a graph showing analysis of the amount of nitric oxide synthesis by the nitric oxide assay method of macrophages (Raw 264.7 cells) treated by experimental example 1 of the present invention.
FIG. 3 is a graph showing the measurement of the concentration of interleukin-6 (IL-6) in blood of the experimental group 1, arthritis-induced group and control group treated by Experimental example 2 of the present invention.
Fig. 4 is a graph showing measurement of bone volume by photographing feet of experimental group 1 to experimental group 3, arthritis-induced group, and control group of experimental example 2 of the present invention.
Fig. 5 is a graph showing measurement of bone section thickness by photographing feet of experimental groups 1 to 3, arthritis-inducing group, and control group of experimental example 2 of the present invention.
Fig. 6 is a graph showing the measurement of the number of average sectional fragments by photographing feet of experimental group 1 to experimental group 3, arthritis-inducing group, and control group of experimental example 2 of the present invention.
Fig. 7 is a photograph showing a device for relieving and improving inflammation using a far infrared ray-emitting ceramic composition and low-intensity ultrasonic waves according to the present invention.
Fig. 8 is a photograph showing a thermal stimulation apparatus to which the far infrared ray emitting ceramic composition according to the present invention is applied.
Fig. 9 is a schematic view showing a thermal stimulation process using the far infrared ray emitting ceramic composition used in experimental example 2 of the present invention. (NDC: ceramic composition)
Detailed Description
Hereinafter, preferred embodiments of the present invention and physical properties of each component will be described in detail, which are intended to be explained in sufficient detail to enable those skilled in the art to easily practice the present invention, and are not intended to limit the technical spirit and scope of the present invention.
The device for relieving and improving inflammation using a far infrared ray emitting ceramic composition and low intensity ultrasonic waves according to the present invention comprises: an ultrasonic irradiation unit that generates low-intensity ultrasonic waves to irradiate a site where inflammation occurs; a thermal stimulation part for applying far infrared rays generated by heating the ceramic composition to a site where inflammation occurs; and a control unit for controlling at least one of the frequency band, intensity, and irradiation time of the low-intensity ultrasonic wave and the temperature of the thermal stimulation unit.
Further, the inflammation site may be a bone tissue site damaged by arthritis, and thus the bone tissue site damaged by arthritis may be improved and treated.
When the ultrasonic wave irradiation part is projected to a human tissue, low-intensity ultrasonic waves for increasing a blood flow, increasing metabolism, increasing an elongation of a collagen tissue, increasing a pain threshold, relieving muscle spasm, increasing an enzyme activity, changing a physiological reaction such as a contractile force of skeletal muscles, and the like can be generated and irradiated to a site of inflammation.
The thermal stimulation part forms a ceramic composition emitting a large amount of far infrared rays, which shows an increase in bone volume, an increase in thickness of a bone section, and a decrease in the number of average section fragments, after a heating process, the ceramic composition consisting of medical stone, volcanic rock, carbon, volcanic ash, and biotite, preferably, 100 parts by weight of medical stone, 0.5 to 1.5 parts by weight of volcanic rock, 0.05 to 0.15 parts by weight of carbon, 1 to 3 parts by weight of volcanic ash, and 0.5 to 1.5 parts by weight of biotite.
The Maifanitum is prepared from Maifanitum powder in each cubic centimeter (cm) 3 ) The ultra-porous raw stone having about 3 to 15 ten thousand pores has a very strong adsorption power, contains about 25000 kinds of inorganic salts, and emits a large amount of far infrared rays when heated.
And, the volcanic ash (pozzolan) is composed of volcanic ash, which emits 90% to 97% far infrared rays as a kind of agalmatolite in a wavelength of 5 μm to 20 μm.
In addition, the biotite is a mineral having a far infrared radiation rate about 3 times or more and containing a large amount of germanium as compared with loess and medical stone. The volcanic rock is composed of only pure inorganic substances, and thus not only contains various essential mineral components, but also exhibits characteristics of emitting high-infrared rays.
The ceramic composition consisting of the components is prepared by the following steps: crushing the raw materials, namely respectively crushing medical stone, volcanic rock, carbon, volcanic ash and biotite; a micro-pulverization step of mixing pulverized materials respectively pulverized by the raw material pulverization step, adding water, and then performing micro-pulverization; an air injection step of injecting air so that the finely pulverized material obtained by the fine pulverization step has a particle shape; a molding step of putting the micro ground matter having the particle shape in the air injecting step into a mold and performing pressure molding; a firing step of firing the molded article molded in the molding step; and a polishing step of polishing the surface of the molded product fired in the firing step.
The raw material pulverizing step is a step of pulverizing medical stone, volcanic rock, carbon, volcanic ash and biotite into particles of 350 to 700 meshes, respectively, and if the particle size of the raw material pulverized in the raw material pulverizing step is less than 350 meshes, the fine pulverizing step is difficult to perform due to an excessively large particle size, and if the particle size of the raw material pulverized in the raw material pulverizing step is more than 700 meshes, the efficiency of the fine pulverizing step is improved, but the pulverizing step may be too long to reduce productivity.
The micro-crushing step comprises the following steps: the pulverized materials respectively pulverized by the above raw material pulverizing step are mixed in the content range as described above, and after 60 to 80 parts by weight of water is mixed with respect to 100 parts by weight of the above mixture, they are pulverized to a particle size of 1000 to 3000 mesh using a ball mill.
In this case, if the particle size of the pulverized material finely pulverized through the above process is less than 1000 mesh, the surface of the molded product becomes rough and the molded product is not beautiful, and if the particle size of the pulverized material is greater than 3000 mesh, the productivity is lowered.
The air injection step is a step of injecting air so that the pulverized material pulverized by the fine pulverization step takes a granular shape, and is a step of injecting air so that the pulverized material pulverized by the fine pulverization step takes a granular shape using a spray dryer.
In the above process, the injection of air to have a particle shape using a spray dryer is to prevent cracks and fissures from being generated in the product during the pressurization process performed in the above molding step.
The molding step is a step of putting the fine pulverized material having the particle shape in the air injection step into a mold and performing pressure molding, and is realized by a process of putting the fine pulverized material having the particle shape in the air injection step into a mold and performing pressure molding, and the pressure molding is a process of manufacturing a mold having a shape to be manufactured, filling the oil air compressor with powder having the particle shape, and then applying a response pressure according to the kind of a product to perform molding. In this case, if the above-mentioned finely pulverized material in a particle shape can be used as it is, it can be used by being pulverized again.
The firing step is a step of firing the molded article molded in the molding step, and is implemented by firing the molded article molded in the molding step at a temperature of 900 to 1200 ℃ for 10 to 24 hours.
In the above-mentioned firing step, if the firing temperature is lower than 900 ℃, the firing cannot be completely performed, and the appearance quality of the molded article is deteriorated, and if the firing temperature is higher than 1200 ℃, the mechanical properties of the molded article are deteriorated. In the firing step, if the firing time is less than 10 hours, the firing cannot be completed, and if the firing time is more than 24 hours, the productivity is lowered.
The polishing step is a step of polishing the surface of the molded product fired in the firing step, and is realized by the following steps: when the firing step is completed at the above-described temperature and time, the fired molded product is naturally cooled, and the surface of the naturally cooled molded product is polished.
The grinding step is performed by a process of grinding after cutting the surface of the molded object by putting a cutting stone into a vibration polisher or a centrifugal polisher, in which case the cutting time is about 20 hours to 30 hours on average.
After the cutting process for the above-described time, the molded article whose surface has been cut is put into a polishing and grinding machine, and a polishing stone and a polishing compound are put therein to perform polishing and grinding.
In the case where cutting and polishing are performed in two steps as described above, when the ceramic composition is used as a medical device for necklaces, bracelets, and the like, the merchantability is improved due to its aesthetic appearance. The ceramic composition emitting far infrared rays through the process as described above is manufactured, firmly packaged and sold in a proper size and weight, and can be applied to medical devices such as electric pads, thermal treatment devices, waistbands, seat cushions, pillows, bracelets, necklaces, and the like.
Further, a step of coating the pulverized material pulverized in the pulverizing step with silver nanoparticles may be performed between the pulverizing step and the air injecting step. When the finely pulverized product is coated with silver nanoparticles, the antibacterial property of the far infrared ceramic composition is greatly improved.
In this case, a mixed solution is prepared by mixing a surfactant and silver nitrate in the process of applying the fine silver nanoparticles to the finely pulverized product. In this case, a cationic, anionic, nonionic surfactant can be used as the above surfactant. When an aqueous solution containing sodium borate dissolved therein is added as a reducing agent to the mixed solution, the color of the mixed solution gradually changes from colorless to dark brown and fine silver particles are generated during the reduction of the dissolved silver particles. In this case, the added surfactant hinders the growth of the fine silver particles, thereby obtaining a colloid in which the silver nanoparticles are dispersed in the aqueous solution. In order to remove unreacted substances and impurities after the generation of the silver nanoparticles, the generated silver nanoparticles are separated into silver nanoparticles and a solution by centrifugation at a speed of 5000rpm to 8000rpm, and the supernatant is discarded and the washing is repeated three times to finally prepare a silver colloid stabilized by a surfactant. In order to obtain a powder in which the fine silver nanoparticles thus prepared are uniformly dispersed, a 0.5% hydrochloric acid (HCl) or hydrofluoric acid (HF) solution is added to the finely pulverized product and subjected to an acid treatment, and the finely pulverized product coated with the nanoparticles is produced by mixing and stirring the mixture with a stable silver colloid, and can be used by drying the finely pulverized product so that the finely pulverized product is formed into a particle shape by injecting air using a spray dryer.
In this case, the acid treatment is performed because a plurality of silanol groups (SiOH) are formed on the surface of the finely pulverized product and impurities are removed, so that the silver nanoparticles can be easily fixed. In this case, it is preferable that the mixing ratio of the finely pulverized material to the silver colloid is 100:0.1 part by weight to 100:0.4 part by weight, but is not limited thereto.
The control part controls the low intensity ultrasonic wave to have a frequency band of 0.5MHz to 1.5MHz and a frequency of 100mW/cm 2 To 150mW/cm 2 To show inflammation relief and improvementThe low intensity ultrasonic wave is preferably controlled to have a frequency band of 1.1MHz and 120mW/cm 2 Strength of (1): 9 pulse duration, 50% duty cycle.
The control unit controls the low-intensity ultrasonic wave to have an irradiation time of 15 to 25 minutes each time, and preferably controls the low-intensity ultrasonic wave to have an irradiation time of 20 minutes each time.
And, the control part controls the thermal stimulation part to be heated to a temperature of 35 to 40 ℃ so as to radiate far infrared rays from the ceramic composition constituting the thermal stimulation part in a large amount, and most preferably, controls the thermal stimulation part to be heated to a temperature of 38 ℃.
Also, the operation method of the device for alleviating and improving inflammation according to the present invention includes: generating the low-intensity ultrasonic wave to irradiate an inflammation part; applying far infrared rays generated by heating the ceramic composition to an inflammation site; and controlling at least one of a frequency band, intensity, and irradiation time of the low-intensity ultrasonic wave to be irradiated, and a heating temperature of the ceramic composition.
The inflammation site may be a bone tissue site damaged by arthritis, and thus the bone tissue site damaged by arthritis may be improved and treated.
In this case, the above ceramic composition is the same in terms of components, contents, preparation method and effects as described in the above device for alleviating and improving inflammation using the far infrared ray-emitting ceramic composition and low intensity ultrasonic waves, and thus, the description thereof will be omitted.
The controlling step controls the low intensity ultrasonic wave to be in a frequency band of 0.5MHz to 1.5MHz and at 100mW/cm 2 To 150mW/cm 2 The low-intensity ultrasonic wave is preferably controlled to have a frequency band of 1.1MHz and 120mW/cm 2 Strength of (1): 9 pulse duration, 50% duty cycle.
The ultrasonic waves controlled by the above control step are irradiated at a frequency of 2 to 4 times per week for 3 to 5 weeks for 15 to 25 minutes each time, preferably 3 times per week for 4 weeks for 20 minutes each time.
In the controlling step, the heating temperature of the ceramic composition is controlled to 35 to 40 ℃, preferably 38 ℃.
And, the ceramic composition heated by the above-mentioned control step is applied to the inflammation site at a frequency of 4 to 6 times per week for 3 to 5 weeks, preferably at a frequency of 5 times per week for 4 weeks at 40 to 80 minutes per time.
Hereinafter, the operation method of the device for relieving and improving inflammation using the far infrared ray-emitting ceramic composition and low-intensity ultrasonic waves according to the present invention and the effects produced by the operation method thereof will be described with reference to experimental examples.
Preparation example 1: preparation of ceramic composition emitting far infrared rays
Pulverizing Maifanitum, volcanic rock, carbon, volcanic ash and biotite respectively in a size of 350 mesh to 700 mesh, mixing 95.9kg of Maifanitum, 1kg of volcanic rock, 0.1kg of carbon, 2kg of volcanic ash and 1kg of biotite respectively pulverized to prepare a mixture, mixing 70kg of water with 100kg of the above mixture, pulverizing into a particle size of 1000 mesh to 3000 mesh using a ball mill, granulating by injecting air into the pulverized product pulverized by the above process using a spray dryer, putting the granulated pulverized product into a mold and compression-molding, firing the compression-molded product at 1050 ℃ for 17 hours, cutting the fired product, putting into a polishing mill, adding a polishing stone and a polishing compound, and preparing a ceramic composition emitting far infrared rays by a polishing and grinding process.
Experimental example 1: evaluation of NDC-stimulated anti-inflammatory effects in Raw 264.7 cells (cells)
Culture of Raw 264.7 cells and LPS treatment
In order to observe the immune response, raw 264.7 cells (37 ℃, 5% CO) were cultured in an incubator (incubator) 2 ). The cell culture is divided into pairsIrradiation group, inflammation inducing group, ceramic composition for emitting far infrared ray, and low intensity ultrasonic wave stimulating group. To induce inflammation, lipopolysaccharide (LPS) was treated at a concentration of 1. Mu.g/mL. The ceramic composition emitting far infrared rays was cultured by placing the ceramic composition emitting far infrared rays in the manner as prepared in preparation example 1 above and below the corresponding Cell culture dish (Cell culture dish) in an incubator, and low-intensity ultrasonic stimulation was performed by generating 1.1MHz and 120mW/cm 2 The transducer of low intensity ultrasound is contacted to the lower part of the corresponding cell culture dish for stimulation, and for ultrasonic stimulation, an ultrasonic stimulation gel is coated between the dish and the transducer.
FIG. 1 shows the analysis of inducible nitric oxide synthase protein of macrophages (Raw 264.7 cells) treated by Experimental example 1 of the present invention by Western blotting (Western blot).
As shown in fig. 1, it was found that the expression of inducible nitric oxide synthase protein was significantly reduced in the ceramic composition emitting far infrared rays by the device of the present invention and the experimental group (LPS-NDC-U) stimulated by intense ultrasonic waves, as compared to the inflammation-inducing group (LPS).
Fig. 2 shows the amount of nitric oxide synthesized by macrophages (Raw 264.7 cells) treated in experimental example 1 of the present invention, which were analyzed by a nitric oxide measurement method.
( However, the measurement of nitric oxide uses a nitric oxide measurement method using Griess reagent (Griess reagent) and is a method of: after centrifugation of the Sample (Sample), 100. Mu.L of each supernatant was separated, and 100. Mu.L of Griess reagent (Griess reagent) was reacted on a 96-well plate (well plate) at room temperature for 10 minutes, and then the absorbance was measured at 595 nm. )
As shown in fig. 2, it was found that the amount of nitric oxide synthesized by the ceramic composition emitting far infrared rays by the device of the present invention and the test group (LPS-NDC-U) stimulated by low intensity ultrasonic waves was significantly reduced as compared to the inflammation-inducing group (LPS) or the control group (Con).
Experimental example 2: observation of the IL-6 concentration in blood in small animals induced with rheumatoid arthritis (RA + NDC + U)
After one week and acclimatization of experimental rats (C57 BL6, male, 8 weeks old) provided with a basic diet (solid feed, cargill Agri punina gmbh, qunshan, korea/free water), 10 animals were placed in each group to give each group a similar average body weight.
Experimental group 1: arthritis was induced by injecting 0.05mL of an arthritis-inducing substance, which was prepared by mixing Complete Freund's Adjuvant (CFA, complete free's Adjuvant) with physiological saline at a ratio of 1:1 by weight ratio, and after one week from the time of arthritis induction, the device for improving and treating bone tissue damaged by arthritis according to the present invention having the thermal stimulation part composed of the ceramic composition prepared by the above preparation example 1 interposed at a bone tissue site of arthritis induction was thermally stimulated at a temperature of 38 ℃ for 1 hour at a frequency of 5 times per week for 4 weeks while applying low-intensity ultrasonic waves (frequency of 1.1 MHz), 120mW/cm to the bone tissue site of arthritis induction through the ultrasonic irradiation part 2 Intensity (intensity), 1: pulse duration (pulse duration), 50% duty cycle (duty cycle) of 9 for 4 weeks, 3 days per week, 20 minutes each time.
Experimental group 2: arthritis was induced by injecting 0.05mL of an arthritis-inducing substance, which was prepared by mixing Complete Freund's Adjuvant (CFA, complete free's Adjuvant) with physiological saline at a ratio of 1:1, and after one week from the time of inducing arthritis, the site where arthritis occurred was placed on the ceramic composition prepared in preparation example 1, and heat stimulation was performed at 38 ℃ for 1 hour each time for 4 weeks at a frequency of 5 times per week.
Experimental group 3: arthritis was induced by injecting 0.05mL of an arthritis-inducing substance prepared by mixing Complete Freund's Adjuvant (CFA, complete free's Adjuvant) with physiological saline at a ratio of 1:1 by weight ratio, and mixing the components,after one week from the time of arthritis induction, a low-intensity ultrasonic wave (frequency of 1.1 MHz) and 120mW/cm were irradiated to the arthritis-induced site 2 Intensity (intensity), 1: pulse duration (pulse duration), 50% duty cycle (duty cycle) of 9 for 4 weeks, 3 days per week, 20 minutes each.
Arthritis-inducing group: arthritis was induced by injecting 0.05mL of an arthritis-inducing substance prepared by mixing Complete Freund's Adjuvant (CFA, complete free's Adjuvant) with physiological saline at a ratio of 1:1, and left for 5 weeks from the time of arthritis induction.
Control group: 10 male rats (C57 BL 6) of 8 weeks of age.
The average values of the IL-6 concentration in blood of the test group 1, the arthritis-inducing group and the control group treated in the test example 2 of the present invention were measured and shown in FIG. 3.
Experimental group 1: the concentrations of interleukin-6 in blood of the arthritis-inducing group and the control group were measured by collecting blood from hearts of the experimental group and the control group, isolating only serum with an ethylenediaminetetraacetic acid micro-container (EDTA micro-feeder) (BD biosciences, USA) to be used as a sample, and quantifying interleukin-6 in serum of mice by an enzyme-linked immunological assay (ELISA Kit, ab100712, abcam, san Francisco, calif., USA) using a Mouse interleukin-6 ELISA Kit (Mouse IL-6ELISA Kit).
The experimental method was performed according to the ELISA specification of the manufacturer (Abcam), and the results are shown in fig. 3 below, which shows that the concentration of interleukin-6 was not measured in the experimental group (RA + NDC + U) compared to the arthritis-inducing group (RA) in the same manner as in the control group (Con).
Bone volume was measured by photographing the feet of the experimental groups 1 to 3, the arthritis-induced group, and the control group of the above experimental example 2 and is shown in fig. 4.
{ however, foot photographing was performed using In vivo Micro computer tomography (In-vivo Micro CT) (Skyscan 1176, bruker, germany), and feet were photographed by respiratory anesthesia on Day 0 (Day 0) and Day 28 (Day 28) (before arthritis induction, 4 weeks after stimulation). }
As shown in fig. 4 below, it was found that the bone volume of the experimental group 1 (RA + NDC + U), the experimental group 2 (RA + NDC), and the experimental group 3 (RA + U) of the present invention was significantly increased as compared to the arthritis-induced group (RA) or the control group (Con).
The thickness of the bone cross section was measured by photographing the feet of the experimental groups 1 to 3, the arthritis-inducing group, and the control group of the experimental example 2, and is shown in fig. 5.
{ however, foot photographing was performed using In vivo Micro computer tomography (In-vivo Micro CT) (Skyscan 1176, bruker, germany), and feet were photographed by respiratory anesthesia on Day 0 (Day 0) and Day 28 (Day 28) (before arthritis induction, 4 weeks after stimulation). }
As shown in fig. 5 below, it was found that the thickness of the bone section of the experimental group 1 (RA + NDC + U) of the present invention was significantly increased compared to the arthritis-induced group (RA) or the control group (Con).
The average number of cross-sectional fragments was measured by photographing the feet of the experimental groups 1 to 3, the arthritis-inducing group, and the control group of the experimental example 2, and is shown in fig. 6.
{ however, foot photography was performed using In vivo computerized tomography (In-vivo Micro CT) (Skyscan 1176, bruker, germany) and feet were photographed by respiratory anesthesia on Day 0 (Day 0) and on Day 28 (Day 28) (before arthritis induction, after 4 weeks of stimulation). }
As shown in fig. 6 below, the average number of cross-sectional fragments was significantly reduced in the experimental group (RA + NDC + U) of the present invention compared to the arthritis-induced group (RA), and compared to the control group (Con).
Therefore, the device for relieving and ameliorating inflammation using the far infrared ray-emitting ceramic composition and low-intensity ultrasonic waves according to the present invention warm-stimulates the inflammatory site with a ceramic emitting a large amount of far infrared rays, and shows a radical effect of relieving and ameliorating inflammation by irradiating low-intensity ultrasonic waves that increase the movement of cells or the synthesis of growth factors and decrease the expression of inducible nitric oxide synthase protein.
Also, the apparatus for improving and treating bone tissue damaged by arthritis according to the present invention using far infrared ray radiating ceramic composition and low intensity ultrasonic wave warm stimulates the bone tissue site damaged by arthritis with the warm stimulating part consisting of ceramic composition radiating a large amount of far infrared ray to increase bone volume, increase bone section thickness and reduce the number of average section fragments, and shows the effect of improving and treating bone tissue damaged by arthritis by irradiating low intensity ultrasonic wave.
Claims (10)
1. A device for relieving and ameliorating inflammation using a far infrared ray emitting ceramic composition and low intensity ultrasonic waves, comprising:
an ultrasonic irradiation unit that generates low-intensity ultrasonic waves to irradiate a site where inflammation occurs;
a thermal stimulation unit for applying far infrared rays generated by heating the ceramic composition to a site where inflammation occurs; and
a control unit for controlling at least one of the frequency band, intensity and irradiation time of the low-intensity ultrasonic wave and the temperature of the thermal stimulation unit,
the control unit is used for controlling the low-intensity ultrasonic wave to have a frequency band of 0.5MHz to 1.5MHz and 100mW/cm 2 To 150mW/cm 2 Strength of (1): the pulse duration of 9 and the condition of 50% duty cycle,
the ceramic composition consists of 100 parts by weight of medical stone, 0.5 to 1.5 parts by weight of volcanic rock, 0.05 to 0.15 parts by weight of carbon, 1 to 3 parts by weight of volcanic ash and 0.5 to 1.5 parts by weight of biotite.
2. The device for alleviating or ameliorating inflammation using a far infrared ray-emitting ceramic composition and low-intensity ultrasonic waves according to claim 1, wherein the site of inflammation is a bone tissue site damaged by arthritis.
3. The apparatus for relieving and improving inflammation using far infrared radioactive ceramic composition and low intensity ultrasonic wave according to claim 1, wherein the control part controls the low intensity ultrasonic wave to have an irradiation time of 15 to 25 minutes each time.
4. The apparatus for relieving and improving inflammation using far infrared radioactive ceramic composition and low intensity ultrasonic wave according to claim 3, wherein said control part controls said low intensity ultrasonic wave to have an irradiation time of 20 minutes each time.
5. The apparatus for relieving and improving inflammation using far infrared ray radioactive ceramic composition and low intensity ultrasonic wave according to claim 1, wherein the control part controls the thermal stimulation part to be heated to a temperature of 35 to 40 ℃.
6. The device for alleviating or ameliorating inflammation using a far infrared radiation ceramic composition and low intensity ultrasound according to claim 5, wherein the control unit controls the thermal stimulation unit to heat to a temperature of 38 ℃.
7. The device for alleviating and improving inflammation using far infrared ray emitting ceramic composition and low intensity ultrasonic wave according to claim 1, wherein the ceramic composition is prepared by the steps of:
crushing the raw materials, namely respectively crushing medical stone, volcanic rock, carbon, volcanic ash and biotite;
a micro-pulverization step of mixing pulverized materials respectively pulverized in the raw material pulverization step, adding water, and micro-pulverizing;
an air injection step of injecting air so that the pulverized material pulverized in the fine pulverization step has a particle shape;
a molding step of putting the micro pulverized material having the particle shape in the air injecting step into a mold and performing pressure molding;
a firing step of firing the molded article molded in the molding step; and
and a polishing step of polishing the surface of the molded product fired in the firing step.
8. The apparatus for relieving and improving inflammation using a far infrared ray-emitting ceramic composition and low-intensity ultrasonic waves according to claim 7, wherein a step of coating the pulverized material pulverized by the pulverizing step with silver nano-particles is further performed between the pulverizing step and the air injecting step.
9. The apparatus for relieving and improving inflammation using far infrared ray-emitting ceramic composition and low intensity ultrasonic wave as claimed in claim 7, wherein in the micro-pulverizing step, pulverized materials respectively pulverized by the raw material pulverizing step are mixed to prepare a mixture, and after 60 to 80 parts by weight of water is added to 100 parts by weight of the mixture, the mixture is pulverized to a size of 1000 to 3000 mesh.
10. The device for alleviating and improving inflammation using a far infrared ray-emitting ceramic composition and low-intensity ultrasonic waves according to claim 7, wherein in the firing step, the molded article molded by the molding step is fired at a temperature of 900 to 1200 ℃ for 10 to 24 hours.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190106078A KR102297628B1 (en) | 2019-08-28 | 2019-08-28 | Apparatus for the improvement and treatment of bone tissue damaged by arthritis using far-infrared emitting ceramic composition and ultrasound |
| KR10-2019-0106055 | 2019-08-28 | ||
| KR10-2019-0106044 | 2019-08-28 | ||
| KR10-2019-0106078 | 2019-08-28 | ||
| KR1020190106044A KR20210025954A (en) | 2019-08-28 | 2019-08-28 | Device for alleviation and improvement of edema using low intensity ultrasound |
| KR1020190106055A KR102297627B1 (en) | 2019-08-28 | 2019-08-28 | Inflammation alleviation and remediation apparatus using far-infrared emitting ceramic composition and ultrasound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112439132A CN112439132A (en) | 2021-03-05 |
| CN112439132B true CN112439132B (en) | 2023-03-28 |
Family
ID=74733108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911228027.5A Active CN112439132B (en) | 2019-08-28 | 2019-12-04 | Device for improving arthritis using ceramic composition and low intensity ultrasonic wave |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112439132B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671582B (en) * | 2022-12-29 | 2023-08-01 | 北京大学第三医院（北京大学第三临床医学院） | Low-intensity pulse ultrasonic instrument for reducing cerebral inflammation and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100776781B1 (en) * | 2006-10-24 | 2007-11-29 | (주) 힐스코 | Stimulus apparatus for multiple manual therapy |
| KR100907656B1 (en) * | 2009-03-10 | 2009-07-14 | 칭다오 누가 메디컬 컴퍼니 리미티드 | Method for producing bio-ceramic for medical instruments |
| KR20140028894A (en) * | 2012-08-31 | 2014-03-10 | (주)미르시스템 | Low-intensity ultrasonic medical treatment equipment for arthritis |
| CN108002806A (en) * | 2017-03-29 | 2018-05-08 | 青岛创恩康环保设备有限公司 | A kind of far-infrared radiator, preparation method and purifier for non-contact water purification |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4660024B2 (en) * | 2001-06-26 | 2011-03-30 | 帝人株式会社 | MMP activity lowering apparatus and method |
| KR100537343B1 (en) * | 2004-10-01 | 2005-12-19 | 주식회사 듀플로젠 | An ultrasonic equipment for treatment of osteoarthritis |
| CN101182215A (en) * | 2007-10-31 | 2008-05-21 | 青岛丽可医疗器械有限公司 | Biological chemical ceramic for medical device and preparation method thereof |
| BR112016026001B1 (en) * | 2014-05-05 | 2021-08-17 | Multiple Energy Technologies Llc | BIOCERAMIC COMPOSITIONS AND BIOMODULATING USES OF THEM |
| KR102470451B1 (en) * | 2016-05-19 | 2022-11-23 | 요하치 야마시타 | Ultrasonic irradiation device and system and ultrasonic irradiation method |
-
2019
- 2019-12-04 CN CN201911228027.5A patent/CN112439132B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100776781B1 (en) * | 2006-10-24 | 2007-11-29 | (주) 힐스코 | Stimulus apparatus for multiple manual therapy |
| KR100907656B1 (en) * | 2009-03-10 | 2009-07-14 | 칭다오 누가 메디컬 컴퍼니 리미티드 | Method for producing bio-ceramic for medical instruments |
| KR20140028894A (en) * | 2012-08-31 | 2014-03-10 | (주)미르시스템 | Low-intensity ultrasonic medical treatment equipment for arthritis |
| CN108002806A (en) * | 2017-03-29 | 2018-05-08 | 青岛创恩康环保设备有限公司 | A kind of far-infrared radiator, preparation method and purifier for non-contact water purification |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112439132A (en) | 2021-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1026064C (en) | Preparation process for composite inhibiting activated | |
| CN101720939B (en) | Giant salamander meat and bone meal capsules, preparation method and application thereof | |
| CN101856114B (en) | Health food with bone intensity enhancing function and preparation method thereof | |
| CN112439132B (en) | Device for improving arthritis using ceramic composition and low intensity ultrasonic wave | |
| KR101602798B1 (en) | Composition comprising the tourmanium containing anti-allergic effect | |
| KR102297627B1 (en) | Inflammation alleviation and remediation apparatus using far-infrared emitting ceramic composition and ultrasound | |
| CN1883309A (en) | A deer bone granule | |
| CN112516165B (en) | Ceramic composition for preventing, treating or improving diabetes and preparation method thereof | |
| KR102297628B1 (en) | Apparatus for the improvement and treatment of bone tissue damaged by arthritis using far-infrared emitting ceramic composition and ultrasound | |
| KR102339100B1 (en) | Ceramic composition for inflammatory relief or improvement and method thereof | |
| RU2230464C1 (en) | Method for processing algae for preparing product "lamifaren" | |
| CN110179836A (en) | The synthetic method of the tumor combined therapeutic nanometer formulation of CuS mineralising sendai virus | |
| CN112441825A (en) | Ceramic composition for relieving or improving inflammation and preparation method thereof | |
| KR102339099B1 (en) | Ceramic composition for edema relief or improvement and method thereof | |
| KR102025169B1 (en) | Water-Soluble Jade Extract and Preparation Method Thereof | |
| Freire et al. | Evaluation of bone repair after radiotherapy by photobiomodulation-an animal experimental study | |
| CN1132621C (en) | Tibetans medicine for treating cardiac and cerebral vascular disease and white pulse disease | |
| CN109568800B (en) | Preparation method of reusable physiotherapy patch capable of improving blood circulation and relieving rheumatism | |
| CN1309318C (en) | Body building nutrient | |
| KR0129551B1 (en) | Skim-adhesive containing nephrite jade powder | |
| CN108936960A (en) | A kind of independent assortment energy of a quantum unit insole | |
| CN109430885A (en) | It is a kind of using oligopeptide as nutritional agents of carrier and preparation method thereof | |
| CN110357574A (en) | A kind of magnetic therapy stone material and preparation method thereof | |
| EP1945171A1 (en) | A medical device's manufacture and usage in alternative medicine for rehabilitation treatment of chronic diseases | |
| KR20210104208A (en) | Method for manufacturing tongue exercise equipment using mineral minerals and natural chemical components and methods for using the materials for bead pillows and half-bath beads dry sauna, raw stone beads, and porcelain beads |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |